A Phase 1/2 interventional study of Chloroquine Phosphate and PfSPZ Challenge in Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in Mali. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-12.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing PfSPZ Challenge in Malaria — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria.
Among the 13 studies testing PfSPZ Challenge in Malaria, this one has the largest enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 12th registered.
1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →1 of the 13 studies testing PfSPZ Challenge in Malaria is open now. Recruiting first, the newest first:
University Hospital Tuebingen
Ages 18–45 · Healthy volunteers
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 2
First in 2010; this study’s year is marked. 1 started in 2019.
This study's enrollment of 252 is close to the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 30 across the 13 interventional studies. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 4 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID): 9 open now, 11 under way, none of them phase 3. Of 96 finished, 19 (20%) have results posted.
Among the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 19th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2019, is one of 3 in phase 1/2, and was the 88th registered.
National Institute of Allergy and Infectious Diseases (NIAID)’s Malaria studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing PfSPZ Challenge in Malaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among National Institute of Allergy and Infectious Diseases (NIAID)’s 112 in Malaria:
This tab as a report to print or save as PDF → With an account.
Background:
Malaria remains a major global health problem. Malaria is spread by the bite of mosquitos. Africa is the region of the world where most people get malaria. Sanaria PfSPZ Challenge is a malaria vaccine. Researchers want to see if the vaccine combined with partner drugs can help protect against malaria.
Objective:
To test if injections with 3 monthly doses of Sanaria PfSPZ Challenge, combined with either pyrimethamine (PYR) or chloroquine as a partner drug, is safe, tolerable, and effective.
Eligibility:
Healthy people ages 18-50 years who live in Bancoumana, Mali, or nearby
Design:
Participants will be screened with the Malaria Comprehension Exam to check their understanding of the study. They will have a medical history. They will have a physical exam. They will have blood tests, urine tests, and heart tests.
Participants will join either the pilot study or the main study.
Participants will be assigned to groups. Depending on their group, they will get at least one injection of either a placebo or the vaccine. They may have up to 3 vaccines, 4 weeks apart. The injection will be into a vein with a needle.
Participants will also take pyrimethamine or chloroquine by mouth. They will also take standard doses of antimalarial drugs by mouth.
Participants will have blood tests throughout the study.
Participants may develop a rash or injection site reaction. If this happens, photos of the site may be taken.
Participants will be observed for infection for many days after the injections.
Human studies have shown that immunization by the bite of Plasmodium falciparum (Pf) sporozoite (SPZ)-infected mosquitoes (chemoprophylaxis with sporozoites [CPS]) or by injecting aseptic, purified, cryopreserved sporozoites (SPZ) with needle and syringe (PfSPZ chemoprophylaxis vaccination, Sanaria PfSPZ-CVac) under drug coverage with chloroquine can provide >80% protection against homologous controlled human malaria infection (CHMI) (Roestenberg, McCall et al. 2009, Roestenberg, Teirlinck et al. 2011, Mordmuller, Surat et al. 2017). The protective immunity induced by CPS/PfSPZ-CVac is thought to target sporozoite and liver stage antigens, but the transient parasitemia observed under chloroquine prophylaxis may additionally induce immune responses targeting blood stage parasites that contribute to protection. It is important to understand the contribution of each stage in this model as transient parasitemia in the immunization process adds a safety concern and may impair the development of immunity.
We have conducted two phase 1 studies to explore whether significant protective efficacy can be achieved with exclusively pre-erythrocytic (sporozoite/liver stage) exposure in this model using PYR chemoprophylaxis. This drug, unlike chloroquine, kills the parasites in the liver, so there is no period of transient parasitemia following immunization. These studies in malaria na(SqrRoot) ve adults demonstrated that PfSPZ-CVac (with PYR administered 2 \& 3 days after injection) is safe, well-tolerated, and can prevent subpatent and patent parasitemia after PfSPZ injection. The NCT02511054 study used the same dose (5.12x104 PfSPZ) that has resulted in >80% protection in previous trials of PfSPZ-CVac (chloroquine), showed only 2/9 vaccinees were protected against a homologous (same strain of Pf as the vaccine) CHMI. In trials using irradiated SPZ, increasing the dose of PfSPZ used for immunization has resulted in higher protective efficacy. Therefore, in an ongoing trial, NCT03083847, we have increased the PfSPZ dose about 4-fold up to 2.0x105 PfSPZ, with preliminary results show markedly improved protection against both homologous and heterologous CHMI in healthy US adults (7/8 and 4/4 study subjects uninfected, respectively). This is the first demonstration that the PfSPZ-CVac approach can confer sterile protection without blood stage exposure.
Building on these promising results from PfSPZ-CVac (pyrimethamine) in the US, this proposed study in a malaria-endemic, adult population in Bancoumana, Mali will initially assess, in a pilot phase, the safety and tolerability of still higher doses of PfSPZ Challenge (4.0x105 PfSPZ) in combination with PYR (day 0;) or chloroquine (days -2, +5). The higher PfSPZ dose is hypothesized to be necessary to achieve significant efficacy against naturally transmitted malaria in malaria-experienced populations. Once this higher dose of PfSPZ is determined to be safe and tolerable and that earlier PYR dosing prevents patent parasitemia, the main phase will explore the effect of both earlier PYR dosing and a higher dosage of PfSPZ used for immunization in the development of protective immunity against natural malaria infection. The results of this study will contribute to understanding the targets and mechanisms of immunity against Pf malaria infection, and how the degree of prior exposure to the parasite (pre-erythrocytic and/or erythrocytic stages) impacts these responses and subsequent protective efficacy in field settings.
After completion of follow up in the main phase, all participants that are still enrolled in the study will be offered a booster dose of the vaccine (4th dose) with a single dose of 4x10\^5 PfSPZ Challenge or normal saline (aligned with what they received in the main phase of the study) at approximately 11 months post 3rd vaccination. The booster dose is timed to allow administration well before the beginning of the ensuing malaria transmission season. Participants will then be followed for approximately 6 months to assess safety and vaccine efficacy through this second transmission season.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of must be willing to use reliable (as defined below) from 21 days prior to first PfSPZ Challenge injection to 28 days following last PfSPZ Challenge exposure (or equivalent study day for Arm 5 controls). For the booster phase, this applies from 21 days prior to the booster vaccination to 28 days post booster vaccination.
EXCLUSION CRITERIA:
Pregnancy, as determined by a positive urine or serum human choriogonadotropin (beta-hCG) test (if female)
--NOTE: Pregnancy is also a criterion for discontinuation of any further dosing or non-safety related interventions for that subject.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 400,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\&3 post PfSPZ
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 400,000 PfSPZ with 75 mg pyrimethamine days 2\&3 post PfSPZ
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 400,000 PfSPZ with chloroquine 2 days prior + 5 days post PfSPZibuprofen (if necessary)
Drug: Chloroquine Phosphate · Biological: PfSPZ Challenge · Drug: Coartem · Drug: ibuprofen
Receiving 400,000 PfSPZ with weekly chloroquineibuprofen (if necessary)
Drug: Chloroquine Phosphate · Biological: PfSPZ Challenge · Drug: Coartem · Drug: ibuprofen
Receiving normal saline with 75 mg pyrimethamine day 0 post injection
Drug: Pyrimethamine · Drug: Coartem
Receiving normal saline with 75 mg pyrimethamine days 2\&3 post injection
Drug: Pyrimethamine · Drug: Coartem
Receiving normal saline with weekly chloroquineibuprofen (if necessary)
Drug: Chloroquine Phosphate · Drug: Coartem · Drug: ibuprofen
Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ (if necessary)
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 300,000 PfSPZ with 75 mg pyrimethamine day 0 post PfSPZ
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\&3 post PfSPZ (if necessary)
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Receiving 300,000 PfSPZ with 75 mg pyrimethamine days 2\&3 post PfSPZ (if necessary)
Biological: PfSPZ Challenge · Drug: Pyrimethamine · Drug: Coartem
Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia. Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.
Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
Number of Participants With Positive Sensitive Blood Smear (sBS)
Count of participants with positive sensitive blood smear (sBS) occurring after PfSPZ-CVac immunization starting on day 7 post DVI. Only pilot phase arms (Arms 1a, 2a) were analyzed for this outcome measure. Arms 5a and 6a were not performed, as no patent parasitemia was observed in either Arms 1a or 2a, per the protocol.
Time frame: 7 -12 days post-inoculation
Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)
Count of participants with local and systemic grade 3 signs or symptoms lasting more than 48 hours despite adequate management and serious adverse events (SAEs) occurring after PfSPZ-CVac DVI. Only arm 3a was analyzed for this outcome measure, per the protocol objectives.
Time frame: From day of inoculation to 14 days post-inoculation
Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
Count of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after PfSPZ-CVac immunization. This outcome measure applies to main phase arms 1b, 2b, 4a, and 4b. Arms 5b and 6b were not performed as patent parasitemia with the higher dose of PfSPZ was not observed in the pilot phase (Arms 1a, 2a).
Time frame: For the main phase: from the day of inoculation to approximately 6 months post-3rd inoculation. For the booster phase: from the time of inoculation to approximately 6 months post-booster inoculation
| Milestone | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 |
|---|---|---|---|---|---|---|---|
| Started | 4 | 90 | 4 | 60 | 4 | 54 | 36 |
| Completed | 4 | 83 | 4 | 53 | 4 | 47 | 32 |
| Not completed | 0 | 7 | 0 | 7 | 0 | 7 | 4 |
| Withdrew: Travel | 0 | 4 | 0 | 4 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 3 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Received wrong vaccine and travelled | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Unable to make study visit | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Count of participants with positive sensitive blood smear (sBS) occurring after PfSPZ-CVac immunization starting on day 7 post DVI. Only pilot phase arms (Arms 1a, 2a) were analyzed for this outcome measure. Arms 5a and 6a were not performed, as no patent parasitemia was observed in either Arms 1a or 2a, per the protocol.
| Participants | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 2a - Pilot/Safety: Dosing Interval on Days: 1 |
|---|---|---|
| Number of Participants With Positive Sensitive Blood Smear (sBS) | 0 | 0 |
Count of participants with local and systemic grade 3 signs or symptoms lasting more than 48 hours despite adequate management and serious adverse events (SAEs) occurring after PfSPZ-CVac DVI. Only arm 3a was analyzed for this outcome measure, per the protocol objectives.
| Participants | 3a - Pilot/Safety: Dosing Interval on Days: 1 |
|---|---|
| Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs) | 0 |
Count of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after PfSPZ-CVac immunization. This outcome measure applies to main phase arms 1b, 2b, 4a, and 4b. Arms 5b and 6b were not performed as patent parasitemia with the higher dose of PfSPZ was not observed in the pilot phase (Arms 1a, 2a).
| Participants | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 |
|---|---|---|---|---|
| Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs) | 88 | 59 | 51 | 36 |
Collected over One month for pilot phase; eight months for main phase; seven months for booster phase. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1a - Pilot/Safety: Dosing Interval on Days: 1 | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 1/90 (1.1%) | 1/90 (1.1%) | 88/90 (97.8%) |
| 2a - Pilot/Safety: Dosing Interval on Days: 1 | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 0/60 (0%) | 0/60 (0%) | 59/60 (98.3%) |
| 3a - Pilot/Safety: Dosing Interval on Days: 1 | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 0/54 (0%) | 1/54 (1.9%) | 51/54 (94.4%) |
| 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 0/36 (0%) | 0/36 (0%) | 36/36 (100%) |
| Event | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 |
|---|---|---|---|---|---|---|---|
| VolvulusGastrointestinal disorders | 0/4 | 0/90 | 0/4 | 0/60 | 0/4 | 1/54 | 0/36 |
| Gun shot woundInjury, poisoning and procedural complications | 0/4 | 1/90 | 0/4 | 0/60 | 0/4 | 0/54 | 0/36 |
| Event | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 |
|---|---|---|---|---|---|---|---|
| RhinitisInfections and infestations | 0/4 | 48/90 | 0/4 | 38/60 | 1/4 | 27/54 | 22/36 |
| MalariaInfections and infestations | 0/4 | 30/90 | 0/4 | 24/60 | 0/4 | 32/54 | 19/36 |
| HeadacheNervous system disorders | 0/4 | 27/90 | 0/4 | 24/60 | 0/4 | 24/54 | 19/36 |
| Blood creatinine increasedInvestigations | 0/4 | 38/90 | 1/4 | 27/60 | 0/4 | 17/54 | 17/36 |
| LeukopeniaBlood and lymphatic system disorders | 0/4 | 40/90 | 0/4 | 24/60 | 0/4 | 12/54 | 13/36 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 36/90 | 0/4 | 14/60 | 0/4 | 11/54 | 11/36 |
| Dental cariesGastrointestinal disorders | 0/4 | 15/90 | 0/4 | 8/60 | 1/4 | 16/54 | 3/36 |
| ConjunctivitisEye disorders | 0/4 | 9/90 | 0/4 | 7/60 | 0/4 | 14/54 | 8/36 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 1/90 | 0/4 | 1/60 | 1/4 | 0/54 | 2/36 |
| GastritisGastrointestinal disorders | 1/4 | 10/90 | 0/4 | 7/60 | 0/4 | 9/54 | 4/36 |
| Age, Categorical(Participants) | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 90 | 4 | 60 | 4 | 54 | 36 | 252 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 36.0 ± 14.4 | 34.6 ± 10.0 | 23.8 ± 10.8 | 34.5 ± 10.0 | 31.8 ± 10.9 | 34.6 ± 10.0 | 34.9 ± 9.9 | 34.5 ± 10.0 |
| Sex: Female, Male(Participants) | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 27 | 0 | 21 | 3 | 19 | 12 | 84 |
| Male | 2 | 63 | 4 | 39 | 1 | 35 | 24 | 168 |
| Race/Ethnicity, Customized(Participants) | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | Total |
|---|---|---|---|---|---|---|---|---|
| Malinke | 3 | 74 | 3 | 53 | 4 | 48 | 30 | 215 |
| Bozo | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Bambara | 0 | 3 | 0 | 3 | 0 | 3 | 2 | 11 |
| Bobo | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Minianka | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 3 |
| Peulh | 0 | 8 | 0 | 3 | 0 | 2 | 4 | 17 |
| Sarakole | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Sonrhai | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | 1a - Pilot/Safety: Dosing Interval on Days: 1 | 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 2a - Pilot/Safety: Dosing Interval on Days: 1 | 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 3a - Pilot/Safety: Dosing Interval on Days: 1 | 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | Total |
|---|---|---|---|---|---|---|---|---|
| Mali | 4 | 90 | 4 | 60 | 4 | 54 | 36 | 252 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Feb 2021, 20 months.
Results were first posted in Jul 2022, 1 year 5 months after primary completion.
Of 16 phase 1/2 interventional studies under Malaria, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 20 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Chloroquine diphosphate · PfSPZ Challenge · Pyrimethamine
National Institute of Allergy and Infectious Diseases (NIAID) →